# US 2024/0002864 A1 · Systems and Methods for Enhancing Gene Expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002864 A1
- Document ID: US20240002864A1
- Status: Published application
- Kind: A1
- Application number: 17/998,789
- Filed: 2021-05-11
- Published: 2024-01-04
- Earliest claimed: 2020-05-11
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Maria Barna; Kathrin Leppek
- Web page: https://patentgrep.com/patent/US20240002864A1

## CPC

- C12N 15/67: General methods for enhancing the expression
- C12N 2310/531: Stem-loop; Hairpin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Systems and methods for enhancing mRNA translation are disclosed. Some embodiments describe expression constructs for producing a peptide and include a translational enhancer. Additional embodiments describe methods for producing a peptide using a construct including a translational enhancer.

## Claims

### Claim 1

A construct to enhance gene translation, comprising:
a coding region; and
a 5′-UTR located at the 5′ end of the coding region and comprising at least one translational enhancer.

### Claim 2 (depends on 1)

The construct of claim 1, wherein the 5′-UTR further comprises a spacer located between the translational enhancer and the coding region.

### Claim 3 (depends on 2)

The construct of claim 2, wherein the spacer is approximately 100-150 nt in length.

### Claim 4 (depends on 2)

The construct of claim 2, wherein the spacer is selected from the group consisting of: a Hoxa9 native spacer (SEQ ID NO: 15), an actin 5′-UTR (SEQ ID NO: 16), and an inverted actin 5′-UTR (SEQ ID NO: 17).

### Claim 5 (depends on 1)

The construct of claim 1, wherein the translational enhancer is one or more of the following: a Hoxa9 IRES-like element, a stem-loop structure isolated from a Hox gene, SEQ ID NO: 1 or a sequence variant thereof, and SEQ ID NOs: 2-14.

### Claim at position 6

-8. (canceled)

### Claim 9 (depends on 1)

The construct of claim 1, wherein the translational enhancer possesses at least 75% sequence identity to SEQ ID NO: 1.

### Claim 10

A method for producing a peptide, comprising:
obtaining an expression construct possessing a target gene and a 5′-UTR, wherein the expression construct comprises a coding region and a 5′-UTR located at the 5′ end of the coding region and comprising at least one translational enhancer; and
delivering the expression construct to a ribosome for translation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the 5′-UTR further comprises a spacer located between the translational enhancer and the coding region.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The method of claim 11, wherein the spacer is selected from the group consisting of: a Hoxa9 native spacer (SEQ ID NO: 15), an actin 5′-UTR (SEQ ID NO: 16), and an inverted actin 5′-UTR (SEQ ID NO: 17).

### Claim 14 (depends on 10)

The method of claim 10, wherein the translational enhancer is one or more of the following: a Hoxa9 IRES-like element, a stem-loop structure isolated from a Hox gene, SEQ ID NO: 1 or a sequence variant thereof, and SEQ ID NOs: 2-14.

### Claim at position 13

-17. (canceled)

### Claim 18 (depends on 10)

The method of claim 10, wherein the translational enhancer possesses at least 75% sequence identity to SEQ ID NO: 1.

### Claim 19 (depends on 10)

The method of claim 10, further comprising isolating a peptide produced by the ribosome using the expression cassette.

### Claim 20

A medical formulation comprising:
an RNA molecule comprising:
a coding region; and
a 5′-UTR located at the 5′ end of the coding region and comprising at least one translational enhancer.

### Claim 21 (depends on 20)

The medical formulation of claim 20, further comprising one or more of a buffer, a lubricant, a binder, a flavorant, and a coating.

### Claim 22 (depends on 20)

The medical formulation of claim 20, wherein the formulation is delivered to an individual orally, nasally, inhalationally, parentally, intravenously, intraperitoneally, subcutaneously, intramuscularly, intradermally, topically, rectally, intracerebrally, intraventricularly, intracerebroventricularly, intrathecally, intracisternally, intraspinally, perispinally, intraocularly, or intravitreally.

### Claim 23 (depends on 20)

The medical formulation of claim 20, wherein the 5′-UTR further comprises a spacer located between the translational enhancer and the coding region.

### Claim 24 (depends on 23)

The construct of claim 23, wherein the spacer is approximately 100-150 nt in length.

### Claim 25 (depends on 23)

The construct of claim 23, wherein the spacer is selected from the group consisting of: a Hoxa9 native spacer (SEQ ID NO: 15), an actin 5′-UTR (SEQ ID NO: 16), and an inverted actin 5′-UTR (SEQ ID NO: 17).

### Claim 26 (depends on 20)

The construct of claim 20, wherein the translational enhancer is one or more of the following: a Hoxa9 IRES-like element, a stem-loop structure isolated from a Hox gene, SEQ ID NO: 1 or a sequence variant thereof, and SEQ ID NOs: 2-14.

### Claim at position 23

-29. (canceled)

### Claim 30 (depends on 20)

The construct of claim 20, wherein the translational enhancer possesses at least 75% sequence identity to SEQ ID NO: 1.
